Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases

Anoop Narayanan, Shay A. Toner, Joyce Jose

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

SARS-CoV-2, the coronavirus responsible for the current COVID-19 pandemic, encodes two proteases, 3CLpro and PLpro, two of the main antiviral research targets. Here we provide an overview of the structures and functions of 3CLpro and PLpro and examine strategies of structure-based drug designing and drug repurposing against these proteases. Rational structure-based drug design enables the generation of potent and target-specific antivirals. Drug repurposing offers an attractive prospect with an accelerated turnaround. Thus far, several protease inhibitors have been identified, and some candidates are undergoing trials that may well prove to be effective antivirals against SARS-CoV-2.

Original languageEnglish (US)
Pages (from-to)151-165
Number of pages15
JournalBiochemical Society transactions
Volume50
Issue number1
DOIs
StatePublished - Feb 2022

All Science Journal Classification (ASJC) codes

  • Biochemistry

Fingerprint

Dive into the research topics of 'Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases'. Together they form a unique fingerprint.

Cite this